Neuromuscular Disease News and Research

RSS
Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Radical change to Alzheimer’s management

Radical change to Alzheimer’s management

Comprehensive guide to current practice of intraoperative neurophysiology

Comprehensive guide to current practice of intraoperative neurophysiology

28% of health care workers in 'work risk' category will not get flu vaccine

28% of health care workers in 'work risk' category will not get flu vaccine

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Immune reaction to dystrophin may contribute to muscle disease: Study

Immune reaction to dystrophin may contribute to muscle disease: Study

ALS Society of Canada applauds Prime Minister's commitment to ensure benefits for veterans with ALS

ALS Society of Canada applauds Prime Minister's commitment to ensure benefits for veterans with ALS

Study finds genetic change in chromosome 4 causes FSHD

Study finds genetic change in chromosome 4 causes FSHD

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Prosensa, GSK initiate additional programs for DMD

Prosensa, GSK initiate additional programs for DMD

UF administers Lumizyme for late-onset Pompe disease

UF administers Lumizyme for late-onset Pompe disease

UF doctors administer newly available therapy for late-onset Pompe disease

UF doctors administer newly available therapy for late-onset Pompe disease

Pharnext closes €4.8-million Series A funding round

Pharnext closes €4.8-million Series A funding round

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients